Patents Assigned to KYOWA KIRIN CO., LTD.
-
Publication number: 20210107997Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.Type: ApplicationFiled: December 22, 2020Publication date: April 15, 2021Applicants: RIKEN, KYOWA KIRIN CO., LTD.Inventors: Kensaku Sakamoto, Kazumasa Ohtake, Yoshimi Yamaguchi, Shigeyuki Yokoyama, Tatsuo Yanagisawa, Akiko Matsumoto, Akifumi Kato, Yasuhisa Shiraishi, Kaname Kimura, Masakazu Homma
-
Publication number: 20210108207Abstract: The present invention provides, for example, an oligonucleotide derivative or a salt thereof comprising a circular oligonucleotide and a linear oligonucleotide, wherein the circular oligonucleotide and the linear oligonucleotide have base sequences complementary to each other, and form a complex via a hydrogen bond between the complementary base sequences, and a method for producing the same.Type: ApplicationFiled: May 1, 2018Publication date: April 15, 2021Applicant: KYOWA KIRIN CO., LTD.Inventors: Junichiro YAMAMOTO, Fumikazu SHINOHARA, Toshimasa HARUMOTO, Masakazu HOMMA, Kenji HAGIWARA
-
Publication number: 20210077481Abstract: The present invention relates to a therapeutic agent for an ophthalmic disease comprising a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in a nanoparticle form, having a property to be retained in a posterior eye tissue when systemically administered.Type: ApplicationFiled: November 30, 2020Publication date: March 18, 2021Applicant: Kyowa Kirin Co., Ltd.Inventors: Hiroki HANIUDA, Sachiko ENOKIZONO, Tomoyuki NAKAZATO, Takuya TOKUDA, Norie FUJIKI
-
Publication number: 20210060169Abstract: An object of the present invention is to provide a novel IL-2 variant which has improved selectivity for IL-2R??? and selectively activates Tregs. The present invention relates to an IL-2 variant, a method for producing the IL-2 variant, a composition and a therapeutic agent for an immune disease, comprising the IL-2 variant, a method for increasing selectivity of IL-2 for IL-2R???, a method for improving an affinity of IL-2 for an IL-2R? subunit, a method of reducing an affinity of IL-2 for at least one of an IL-2R? subunit and an IL-2R? subunit, and a method for selectively activating regulatory T cells.Type: ApplicationFiled: December 27, 2018Publication date: March 4, 2021Applicant: Kyowa Kirin Co., Ltd.Inventors: Masahiro IKEDA, Shinpei YAMAGUCHI, Masumi MURAKAMI, Hideyuki ONODERA
-
Patent number: 10906990Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.Type: GrantFiled: August 18, 2016Date of Patent: February 2, 2021Assignees: RIKEN, KYOWA KIRIN CO., LTD.Inventors: Kensaku Sakamoto, Kazumasa Ohtake, Yoshimi Yamaguchi, Shigeyuki Yokoyama, Tatsuo Yanagisawa, Akiko Matsumoto, Akifumi Kato, Yasuhisa Shiraishi, Kaname Kimura, Masakazu Homma
-
Publication number: 20210024540Abstract: A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: (wherein, L1 and L2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).Type: ApplicationFiled: March 29, 2019Publication date: January 28, 2021Applicant: KYOWA KIRIN CO., LTD.Inventors: Kenji UCHIDA, Ryohei KAWAI, Keisuke YAMAMOTO, Toshimi KANAI, Hideo IKOTA, Takashi IMAEDA, Kei YOSHIDA
-
Patent number: 10894790Abstract: Provided is a production method of a thiazole derivative represented by the formula (I), which has an adenosine A2A receptor antagonistic action and is useful as a therapeutic agent for, for example, Parkinson's disease, sleep disorder, analgesic resistance to opioid, migraine, movement disorder, depression, anxiety disorder and the like. Also provided is a production method of a compound represented by the formula (C), which contains (i) a step of reacting a compound represented by the formula (A) and a compound represented by the formula (B), and the like: (wherein R1 represents furyl, R4, R5 and R6 are the same or different and each represents lower alkyl or aryl, R2 represents pyridyl or tetrahydropyranyl, and X1 represents halogen).Type: GrantFiled: March 18, 2020Date of Patent: January 19, 2021Assignee: KYOWA KIRIN CO., LTDInventors: Takamasa Sugita, Arata Yanagisawa, Iwao Chujo, Masashi Taga, Akihiro Mimura, Atsushi Tada, Masashi Aoki
-
Patent number: 10894043Abstract: The present invention relates to a therapeutic agent for an ophthalmic disease comprising a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in a nanoparticle form, having a property to be retained in a posterior eye tissue when systemically administered.Type: GrantFiled: September 13, 2017Date of Patent: January 19, 2021Assignee: KYOWA KIRIN CO., LTD.Inventors: Hiroki Haniuda, Sachiko Enokizono, Tomoyuki Nakazato, Takuya Tokuda, Norie Fujiki
-
Publication number: 20200368173Abstract: The present invention provides a nucleic acid-containing lipid nanoparticle comprising an analog of a fatty acid ester of glycerol, and a nucleic acid, wherein the analog is not hydrolyzable by a lipase.Type: ApplicationFiled: August 6, 2018Publication date: November 26, 2020Applicant: KYOWA KIRIN CO., LTD.Inventors: Kentaro HATANAKA, Michihiro MAEMOTO, Shintaro HOSOE
-
Publication number: 20200315968Abstract: The present invention provides a method for producing a pharmaceutical composition containing fine particles of a poorly soluble drug, comprising mixing a sugar or a sugar alcohol with a dispersion of nanoparticles of the poorly soluble drug and granulating the obtained mixture.Type: ApplicationFiled: May 31, 2017Publication date: October 8, 2020Applicant: Kyowa Kirin Co., Ltd.Inventors: Yohei YAMAZOE, Toshiki YAMAOKA, Kenji IWATA
-
Patent number: 10787428Abstract: The present invention provides an ?,?-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): [wherein, “A” represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents —O—, —S—, —SO2—, —NRX1— (wherein, RX1 represents hydrogen atom or lower alkyl), —CHRX2— (wherein, RX2 represents hydrogen atom or hydroxy), —CH?CH—, —CO— or —NH—CO—, and n1 and n2 are the same or different, and each represents 0 or 1].Type: GrantFiled: December 22, 2016Date of Patent: September 29, 2020Assignee: KYOWA KIRIN CO., LTD.Inventors: Tomohiro Danjo, Katsuaki Fujiwara, Tomoyuki Nishikawa, Takahiro Nakajima, Nobumasa Otsubo, Toshihiro Seike
-
Patent number: 10745700Abstract: The present invention relates to a nucleic acid conjugate represented by the following formula 1: wherein X is an oligonucleotide, L1 and L2 are each independently sugar ligand, and S1, S2 and S3 are each independently a linker.Type: GrantFiled: January 30, 2017Date of Patent: August 18, 2020Assignee: KYOWA KIRIN CO., LTD.Inventors: Keiji Uehara, Yasuhiro Suzuki, Hiroto Iwai, Masakazu Homma, Yuichi Fukuda, Tatsuto Kiuchi
-
Publication number: 20200199240Abstract: An object of the present invention is to provide a monoclonal antibody which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The present invention relates to a monoclonal antibody which binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15), or an antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment.Type: ApplicationFiled: July 18, 2018Publication date: June 25, 2020Applicants: KYOWA KIRIN CO., LTD., KYOTO UNIVERSITYInventors: Masayuki KAI, Shinya OGAWA, Makoto TAKETO, Kenji KAWADA, Hideyo HIRAI, Yoshiharu SAKAI, Taira MAEKAWA
-
Publication number: 20200190514Abstract: The present invention provides a double-stranded nucleic acid consisting of a sense-strand nucleic acid and an antisense-strand nucleic acid and comprising a double-strand region having at least 11 base pairs, for suppressing expression of APCS gene, in which an oligonucleotide chain having a chain length of at least 17 nucleotides and at most 30 nucleotides in the antisense-strand nucleic acid is complementary to a target APCS mRNA sequence comprising a base sequence set forth in any one of SEQ ID NOS: 1288 to 1930.Type: ApplicationFiled: May 31, 2018Publication date: June 18, 2020Applicant: KYOWA KIRIN CO., LTD.Inventors: Hiroyuki ARIYAMA, Takuya MURAKAMI, Takashi IMAEDA, Tatsuya MIYAZAWA
-
Publication number: 20200179376Abstract: The present invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof having an inhibitory effect on the production of kynurenine, represented by formula (I): (wherein R6 and R7 may be the same or different and each represent a hydrogen atom or the like, R8, R9, R10, and R11 may be the same or different and each represent a hydrogen atom or the like, R1 represents lower alkyl which may be substituted with cycloalkyl, or the like, and R3 represents optionally substituted aryl or an optionally substituted heterocyclic group).Type: ApplicationFiled: December 4, 2019Publication date: June 11, 2020Applicant: Kyowa Kirin Co., Ltd.Inventors: Yuichi Fukuda, Toshimi Kanai, Yoshisuke Nakasato, Keisuke Kimpara
-
Publication number: 20200157211Abstract: An object of the present invention is to provide a method of enabling efficient structural analysis of a target protein that has been impossible or difficult to analyze so far, by stabilizing the target protein. The present invention provides an anti-BRIL antibody which specifically binds to BRIL or a BRIL fusion protein and an antigen-binding fragment thereof, a nucleic acid encoding the anti-BRIL antibody and the antigen-binding fragment thereof, a vector containing the nucleic acid, an antibody producing cell containing the vector, a method of producing the antibody, and a method of using the antibody in a protein structural analysis.Type: ApplicationFiled: July 12, 2018Publication date: May 21, 2020Applicant: KYOWA KIRIN CO., LTD.Inventors: Hikaru MIYAGI, Michihiko SUZUKI, Junichi SAITO, Hidetsugu ASADA, So IWATA
-
Publication number: 20200147188Abstract: A therapeutic composition including antithrombin gamma for diffuse intravascular coagulation or disseminated intravascular coagulation involving a decrease of antithrombin, or for thrombophilia due to congenital antithrombin deficiency and a method of using the composition are disclosed.Type: ApplicationFiled: December 10, 2019Publication date: May 14, 2020Applicant: KYOWA KIRIN CO., LTD.Inventor: Mayumi MUKAI
-
Patent number: 10646544Abstract: This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.Type: GrantFiled: May 31, 2017Date of Patent: May 12, 2020Assignee: KYOWA KIRIN CO., LTD.Inventors: Makoto Kakitani, Kazuma Tomizuka
-
Patent number: 10639360Abstract: The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.Type: GrantFiled: May 29, 2015Date of Patent: May 5, 2020Assignees: Ultragenyx Pharmaceutical, Inc., Kyowa Kirin Co., Ltd.Inventors: Emil D. Kakkis, Javier San Martin, Tomohiro Sudo
-
Patent number: 10618894Abstract: Provided is a production method of a thiazole derivative represented by the formula (I), which has an adenosine A2A receptor antagonistic action and is useful as a therapeutic agent for, for example, Parkinson's disease, sleep disorder, analgesic resistance to opioid, migraine, movement disorder, depression, anxiety disorder and the like. Also provided is a production method of a compound represented by the formula (C), which contains (i) a step of reacting a compound represented by the formula (A) and a compound represented by the formula (B), and the like: (wherein R1 represents furyl, R4, R5 and R6 are the same or different and each represents lower alkyl or aryl, R2 represents pyridyl or tetrahydropyranyl, and X1 represents halogen).Type: GrantFiled: January 14, 2019Date of Patent: April 14, 2020Assignee: KYOWA KIRIN CO., LTD.Inventors: Takamasa Sugita, Arata Yanagisawa, Iwao Chujo, Masashi Taga, Akihiro Mimura, Atsushi Tada, Masashi Aoki